Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Olaf Penack(Humboldt-Universität zu Berlin), Zinaida Perić(University of Rijeka), Jakob Passweg(University Hospital of Basel), Mutlu Arat(Istanbul Florence Nightingale Hospital), Hildegard Greinix(Medical University of Graz), Mohamad Mohty(Sorbonne Université), Tapani Ruutu(Helsinki University Hospital), Daniel Wolff(University Hospital Regensburg), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Stephan Mielke(Karolinska University Hospital), Francesca Patriarca(Ospedale Santa Maria della Misericordia di Udine), Arnon Nagler(Sheba Medical Center), Mette D. Hazenberg(Amsterdam Neuroscience), Radovan Vrḫovac(University Hospital Centre Zagreb), Carlos Solano(Hospital Clínico Universitario de Valencia), Rafael F. Duarte(Institut Català d'Oncologia), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Monia Marchetti(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Francesca Bonifazi(University of Bologna), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Hélène Schoemans(KU Leuven), Robert Zeiser(University of Freiburg), Nicolaus Kröger(Universität Hamburg)
Cited by 240
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k